Image collage showing Magnet Resonance team, bore of magnet, beating heart, Pharmascan scanner, Stroke evolution, Bio-spec scanner, Diffusion tensor image of rodent brain, Images of a mouse brain, Chicken egg, Tarantula‌The Glasgow Experimental MRI Centre (GEMRIC) is a centre for excellence in pre-clinical MRI situated within the Garscube Campus of Glasgow University.  The centre is housed in a custom-designed building containing two Bruker 7 Tesla pre-clinical MRI systems, along with a fully equipped surgical suite, animal holding rooms and physics workshop. 

The research focus of GEMRIC has a strong inter-disciplinary approach with the GEMRIC team and collaborators bringing together extensive experience in in-vivo animal models of disease, MRI physics and functional MRI (fMRI) which is then applied to wide range of research challenges. Our collaborations with other basic scientists and clinicians foster a translational approach to research, focusing on mechanistic approaches, diagnostic imaging development, longitudinal evaluation of anatomical & pathophysiological information and effects of novel interventions on disease processes.

For further information on MRI and potential collaborations please contact the GEMRIC team.

Principal Investigators:  Goense, Holmes, Macrae, McCabe

History:  GEMRIC was opened in 2004 and funded by a £3.5M grant from the Scottish Higher Education Funding Council (SHEFC). The centre was initially built around a 7T Bruker Biospec MRI system. As a result of GEMRIC's success, the University funded a second Bruker 7T MRI system (£0.6M)  which was installed in 2010.

Grant Highlights:  Since opening in 2004 GEMRIC has contributed to £11.5M in competitive awards (MRC, Brain Tumour, EPSRC, NERC, BHF, Henry Smith, Wellcome Trust).

Publications: Since 2004 GEMRIC has published more than 50 peer reviewed articles, in leading journals (e.g. Stroke, Circulation, Circulation Research, Annals of Neurology, Journal of Cerebral Blood Flow & Metabolism).

Recent news:   Pre-clinical research carried out in GEMRIC to develop  new oxygen-based diagnostic techniques for acute stroke has led to the spin out of a new company Aurum Biosciences in September 2015 (http://www.aurumbiosciences.com)  and the first studies translating these techniques for use in stroke patients (Dani, Annals Neurol. 2010)